The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy
Osteoporosis International · 2024-11 · 35 (11) · 2037-2045
DOI: 10.1007/s00198-024-07180-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis International, online erschienen am 18.09.2024. Verfasst von Marsha M van Oostwaard und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands. m.vanoostwaard@maastrichtuniversity.nl. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Osteoporotic Fractures. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Androgen Deprivation Therapy (ADT) increases long-term fracture risk in prostate cancer. Our study showed a higher fracture risk within six months of ADT use, and current use was associated with a higher risk of fragility fractures. Attention is needed for the prevention of fragility fractures at the start of ADT. PURPOSE: Androgen Deprivation Therapy (ADT) is known to increase long-term fracture risk in men with prostate cancer (PCa), although the risk of fragility fractures remains unclear. This study aims to evaluate the risk of fragility and malignancy-related fractures in men with PCa treated with ADT. METHODS: We conducted a retrospective cohort study of men with PCa. Follow-up time was divided into 30-day intervals and exposure (current, past, or no-ADT use). Current ADT use was stratified by duration of ADT use (≤ 182 days, 183-730 days, and > 730 days). Cause-specific Cox proportional hazard models were used to estimate the risk of fractures. RESULTS: We included 471 patients (mean age 70.5 (± 8.3) years). The mean follow-up time was 5.0 (± 1.7) years in patients who never started ADT, 3.4 (± 2.3) years and 4.1 (± 2.0) years in patients who started ADT at baseline and during follow-up, respectively. In total, 60 patients had a fracture, 48 (80%) fragility, and 12 (20%) malignancy-related fractures. Current ADT use was associated with a higher risk of all fractures (HR 5.10, 95% CI 2.34-11.13) and fragility fractures (HR 3.61, 95% CI 1.57-8.30). The association with malignancy-related fractures could not be studied due to no events during no-ADT use. There was an increased risk of all fractures with longer duration of ADT use. CONCLUSIONS: Current ADT use was associated with a higher risk of fragility fractures than no-ADT use. A higher fracture risk was observed within the first six months of ADT use and persisted for longer durations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands. m.vanoostwaard@maastrichtuniversity.nl.
- NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands. m.vanoostwaard@maastrichtuniversity.nl.
- Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.
- NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
- Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands.
- Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center+, Maastricht, The Netherlands.
Zitieren
APA
van Oostwaard, M. M., Wyers, C. E., Driessen, J. H. M., van Maren, M., de Jong, M., van de Wouw, A. J., Janssen-Heijnen, M. L. G., & van den Bergh, J. P. (2024). The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy. Osteoporosis International, 35(11), 2037-2045. https://doi.org/10.1007/s00198-024-07180-8
Vancouver
van Oostwaard MM, Wyers CE, Driessen JHM, van Maren M, de Jong M, van de Wouw AJ, et al. The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy. Osteoporosis International. 2024;35(11):2037-2045. doi:10.1007/s00198-024-07180-8
BibTeX
@article{vanOostwaard2024,
author = {van Oostwaard, Marsha M and Wyers, Caroline E and Driessen, Johanna H M and van Maren, Maud and de Jong, Marc and van de Wouw, Agnes J and Janssen-Heijnen, Maryska L G and van den Bergh, Joop P},
title = {The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy},
journal = {Osteoporosis International},
year = {2024},
volume = {35},
number = {11},
pages = {2037--2045},
doi = {10.1007/s00198-024-07180-8}
}
EUVIMED